Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia

Fig. 4

Active immunotherapy with tau294–305 epitope to hepatitis B core immunodominant region (T294-HBc) virus-like particle (VLP) vaccine reduced AT8-positive aggregates in Tau.P301S mice. AT8-positive aggregates in brain of mice treated with or without vaccine and of wild-type (WT) mice were detected by using AT8 (1:500) antibody. The AT8-positive aggregates in brain (a), cortex (b), and hippocampal CA1 (c) and dentate gyrus (DG) regions (d) were then quantified by morphometric analysis. e AT8-positive aggregates levels in soluble brain homogenates. The AT8-positive aggregates levels in the brain homogenates were detected by Western blotting using antibody AT8 (1:3000). The signals of Western blot were quantified using IPwin5 Image-Pro Plus software, and β-actin was used as a control. Scale bar is 200 μm (compared with adjuvant-treated mice; *P < 0.05 **P < 0.01, ***P < 0.001, Student’s t test)

Back to article page